These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 18927240)
1. Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the Children's Oncology Group. McCune JS; Salinger DH; Vicini P; Oglesby C; Blough DK; Park JR J Clin Pharmacol; 2009 Jan; 49(1):88-102. PubMed ID: 18927240 [TBL] [Abstract][Full Text] [Related]
2. Real-time dose adjustment of cyclophosphamide in a preparative regimen for hematopoietic cell transplant: a Bayesian pharmacokinetic approach. Salinger DH; McCune JS; Ren AG; Shen DD; Slattery JT; Phillips B; McDonald GB; Vicini P Clin Cancer Res; 2006 Aug; 12(16):4888-98. PubMed ID: 16914577 [TBL] [Abstract][Full Text] [Related]
7. Exposure-Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing. Campagne O; Zhong B; Nair S; Lin T; Huang J; Onar-Thomas A; Robinson G; Gajjar A; Stewart CF Clin Cancer Res; 2020 Apr; 26(7):1563-1573. PubMed ID: 31796512 [TBL] [Abstract][Full Text] [Related]
8. Role of metabolites of cyclophosphamide in cardiotoxicity. Kurauchi K; Nishikawa T; Miyahara E; Okamoto Y; Kawano Y BMC Res Notes; 2017 Aug; 10(1):406. PubMed ID: 28807058 [TBL] [Abstract][Full Text] [Related]
9. Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy. Anderson LW; Chen TL; Colvin OM; Grochow LB; Collins JM; Kennedy MJ; Strong JM Clin Cancer Res; 1996 Sep; 2(9):1481-7. PubMed ID: 9816324 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy. Chinnaswamy G; Errington J; Foot A; Boddy AV; Veal GJ; Cole M Eur J Cancer; 2011 Jul; 47(10):1556-63. PubMed ID: 21482104 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of cyclophosphamide (CP) and 4-OH-CP/aldophosphamide in systemic vasculitis. Belfayol-Pisanté L; Guillevin L; Tod M; Fauvelle F Fundam Clin Pharmacol; 2000; 14(4):415-21. PubMed ID: 11030450 [TBL] [Abstract][Full Text] [Related]
12. A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide. Huitema AD; Mathôt RA; Tibben MM; Rodenhuis S; Beijnen JH J Pharmacokinet Pharmacodyn; 2001 Jun; 28(3):211-30. PubMed ID: 11468938 [TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients. Nath CE; Shaw PJ; Montgomery K; Earl JW Br J Clin Pharmacol; 2007 Aug; 64(2):151-64. PubMed ID: 17324241 [TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin. de Jonge ME; Huitema AD; van Dam SM; Rodenhuis S; Beijnen JH Ther Drug Monit; 2005 Dec; 27(6):756-65. PubMed ID: 16306851 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of carboxyethylphosphoramide mustard formation from 4-hydroxycyclophosphamide by carmustine. Ren S; Slatterly JT AAPS PharmSci; 1999; 1(3):E14. PubMed ID: 11741210 [TBL] [Abstract][Full Text] [Related]
16. Cyclophosphamide, hydroxycyclophosphamide and carboxyethyl phosphoramide mustard quantification with liquid chromatography mass spectrometry in a single run human plasma samples: A rapid and sensitive method development. Shanker Kasudhan K; Patial A; Mehra N; Verma Attri S; Malhotra P; Pattanaik S; Lad D; Patil AN J Chromatogr B Analyt Technol Biomed Life Sci; 2022 May; 1198():123228. PubMed ID: 35385800 [TBL] [Abstract][Full Text] [Related]
17. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation. Sladek NE; Doeden D; Powers JF; Krivit W Cancer Treat Rep; 1984 Oct; 68(10):1247-54. PubMed ID: 6395951 [TBL] [Abstract][Full Text] [Related]
18. ABCC2-mediated biliary transport of 4-glutathionylcyclophosphamide and its contribution to elimination of 4-hydroxycyclophosphamide in rat. Qiu R; Kalhorn TF; Slattery JT J Pharmacol Exp Ther; 2004 Mar; 308(3):1204-12. PubMed ID: 14617693 [TBL] [Abstract][Full Text] [Related]
19. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Chen TL; Kennedy MJ; Anderson LW; Kiraly SB; Black KC; Colvin OM; Grochow LB Drug Metab Dispos; 1997 May; 25(5):544-51. PubMed ID: 9152592 [TBL] [Abstract][Full Text] [Related]
20. Analysis of cyclophosphamide and carboxyethylphosphoramide mustard enantiomers in human plasma and application to clinical pharmacokinetics. Attié de Castro F; Scatena Gdos S; Cass QB; Simões BP; Lanchote VL J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Nov; 971():14-9. PubMed ID: 25261835 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]